Myovant Sciences aspires to redefine care for women and men through purpose-driven science, empowering medicines and transformative advocacy.
Our clinical program focuses on developing differentiated solutions that may address high unmet need areas within women’s health and hormone-sensitive oncology. We continuously explore current molecules to potentially expand indications and seek new scientific innovations to enter additional therapeutic areas.
Our current portfolio consists of two molecules, relugolix and MVT-602:
- Relugolix is a gonadotropin-releasing hormone (GnRH) receptor antagonist that reduces sex hormones such as testosterone, estradiol, and progesterone. Relugolix is available as a 120 mg tablet and as a combination tablet (relugolix 40 mg, estradiol 1 mg and norethindrone acetate 0.5 mg). Relugolix is marketed in multiple indications internationally and is currently under investigation for certain uses.
- MVT-602 is an oligopeptide kisspeptin-1 receptor agonist. At present, we’re investigating its potential as a trigger of egg maturation in women undergoing assisted reproduction, including in vitro fertilization (IVF).
Learn more about our clinical trials
We cannot achieve our mission to redefine care for women and for men without clinical trials. All across the world, patients, families, physicians, and clinics support these trials as we strive to turn our purpose-driven science into empowering medicines.
16 Sep 2022
Myovant Recognizes Prostate Cancer Awareness Month with Educational Sponsorships and Online Campaign to Encourage Patients to Speak Up, Seek Support and Be Informed
5 Aug 2022
Myovant Sciences and Pfizer Receive U.S. FDA Approval of MYFEMBREE®, a Once-Daily Treatment for the Management of Moderate to Severe Pain Associated With Endometriosis
You are leaving www.myovant.com, a website provided by Myovant Sciences GmbH.
This link will take you to a different site.